Clinical Trial Update: Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia [Phase 1]

View source ↗

Summary

Clinical trial update: A Phase 1 study is evaluating time-limited therapy with ibrutinib followed by bendamustine and rituximab in Waldenström macroglobulinemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Waldenström Macroglobulinemia (WM) | Phase 1 | Status: NOT_YET_RECRUITING